These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 14575824)

  • 1. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience.
    Sylvester JE; Blasko JC; Grimm PD; Meier R; Malmgren JA
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):944-52. PubMed ID: 14575824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience.
    Sylvester JE; Grimm PD; Blasko JC; Millar J; Orio PF; Skoglund S; Galbreath RW; Merrick G
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):57-64. PubMed ID: 17084544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective stratification of a consecutive cohort of prostate cancer patients treated with a combined regimen of external-beam radiotherapy and brachytherapy.
    Lederman GS; Cavanagh W; Albert PS; Israeli R; Lessing J; Savino M; Volpicella F
    Int J Radiat Oncol Biol Phys; 2001 Apr; 49(5):1297-303. PubMed ID: 11286837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience.
    Sylvester JE; Grimm PD; Wong J; Galbreath RW; Merrick G; Blasko JC
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):376-81. PubMed ID: 20864269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of race on biochemical control in patients with localized prostate cancer treated with permanent brachytherapy: multivariate and matched-pair analyses.
    Lee LN; Barnswell C; Torre T; Fearn P; Kattan M; Potters L
    Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):282-9. PubMed ID: 12023131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of isotope selection in long-term outcomes in patients with intermediate-risk prostate cancer treated with a combination of external beam radiotherapy and low-dose-rate interstitial brachytherapy.
    Wernicke AG; Shamis M; Yan W; Trichter S; Sabbas AM; Goltser Y; Christos PJ; Brennan JS; Parashar B; Nori D
    Urology; 2012 May; 79(5):1098-104. PubMed ID: 22546388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
    Kollmeier MA; Stock RG; Stone N
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer.
    Merrick GS; Butler WM; Galbreath RW; Lief JH
    Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):41-8. PubMed ID: 11516849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
    Ko EC; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice.
    Brachman DG; Thomas T; Hilbe J; Beyer DC
    Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):111-7. PubMed ID: 10924979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy.
    Ding W; Lee J; Chamberlain D; Cunningham J; Yang L; Tay J
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):962-7. PubMed ID: 22494584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isotope selection for patients undergoing prostate brachytherapy.
    Cha CM; Potters L; Ashley R; Freeman K; Wang XH; Waldbaum R; Leibel S
    Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):391-5. PubMed ID: 10487561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma.
    Ellis RJ; Vertocnik A; Kim E; Zhou H; Young B; Sodee B; Fu P; Beddar S; Colussi V; Spirnak JP; Dinchman KH; Resnick M; Kinsella TJ
    Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):362-70. PubMed ID: 12957246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation.
    Stokes SH
    Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):129-36. PubMed ID: 10758314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy.
    Hegde JV; Demanes DJ; Veruttipong D; Raince J; Park SJ; Raman SS; Nickols NG; King CR; Kishan AU; Steinberg ML; Kamrava M
    Brachytherapy; 2017; 16(6):1106-1112. PubMed ID: 28807747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients.
    Joseph N; Taylor C; O'Hara C; Choudhury A; Elliott T; Logue J; Wylie J
    Radiother Oncol; 2016 Nov; 121(2):299-303. PubMed ID: 28029404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical outcome for hormone-naïve patients with high-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external-beam radiation.
    Merrick GS; Butler WM; Lief JH; Galbreath RW; Adamovich E
    Cancer J; 2002; 8(4):322-7. PubMed ID: 12184410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palladium-103 brachytherapy for prostate carcinoma.
    Blasko JC; Grimm PD; Sylvester JE; Badiozamani KR; Hoak D; Cavanagh W
    Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):839-50. PubMed ID: 10705004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.